Comparative Pharmacology
Head-to-head clinical analysis: ONCOVIN versus VINCRISTINE SULFATE PFS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ONCOVIN versus VINCRISTINE SULFATE PFS.
ONCOVIN vs VINCRISTINE SULFATE PFS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vincristine is a vinca alkaloid that binds to tubulin, inhibiting microtubule formation and disrupting mitotic spindle assembly, leading to metaphase arrest and cell death.
Vincristine is a vinca alkaloid that binds to tubulin, inhibiting microtubule formation and disrupting mitotic spindle assembly, causing metaphase arrest in dividing cells.
1.4 mg/m2 IV weekly, maximum single dose 2 mg
1.4 mg/m2 IV push weekly, maximum single dose 2 mg.
None Documented
None Documented
Terminal elimination half-life: approximately 19-155 hours (mean ~85 hours) in adults. In elderly and hepatic impairment, half-life is prolonged. Highly variable due to extensive tissue binding and prolonged terminal phase.
Terminal half-life is 19-155 hours (mean ~85 hours) in adults; prolonged in hepatic impairment or elderly.
Primarily hepatobiliary (fecal) excretion: ~80% as unchanged drug and metabolites via bile into feces. Renal excretion: <10% unchanged in urine. Extensive metabolism in liver via CYP3A4.
Primarily hepatobiliary excretion (70-80%); renal excretion accounts for 10-20% (mostly metabolites); <1% excreted unchanged in urine.
Category C
Category D/X
Vinca Alkaloid
Vinca Alkaloid